Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (81-90 of 265) with videos related to

Pageof 27
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018Selma Ugurel, Rolf-Dieter Kortmann, Peter Mohr, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 27, 2019
S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018Selma Ugurel, Rolf-Dieter Kortmann, Peter Mohr, et al.
AIDS Research and Human Retroviruses|May 9, 2008
Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probabilitySilvia Hahn, Selma Ugurel, Kay-Martin Hanschmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Dose-dependent toxicity of ipilimumab in metastatic melanomaAlexandra Olischewsky, Sofie De Schrijver, Agnes Bankfalvi, et al.
Cancer Immunology, Immunotherapy : CII|January 13, 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaValerie Glutsch, Hermann Kneitz, Anja Gesierich, et al.
Archives of Dermatology|May 20, 2009
A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapyCarl Gebhardt, Marco Averbeck, Uwe Paasch, et al.
Melanoma Research|July 18, 2006
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genesSandra Bloethner, Kari Hemminki, Ranjit K Thirumaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy responseSelma Ugurel, Roland Houben, David Schrama, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Pageof 27

Showing results (81-90 of 265) with videos related to

Sort By:
Pageof 27
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018Selma Ugurel, Rolf-Dieter Kortmann, Peter Mohr, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 27, 2019
S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018Selma Ugurel, Rolf-Dieter Kortmann, Peter Mohr, et al.
AIDS Research and Human Retroviruses|May 9, 2008
Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probabilitySilvia Hahn, Selma Ugurel, Kay-Martin Hanschmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Dose-dependent toxicity of ipilimumab in metastatic melanomaAlexandra Olischewsky, Sofie De Schrijver, Agnes Bankfalvi, et al.
Cancer Immunology, Immunotherapy : CII|January 13, 2021
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaValerie Glutsch, Hermann Kneitz, Anja Gesierich, et al.
Archives of Dermatology|May 20, 2009
A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapyCarl Gebhardt, Marco Averbeck, Uwe Paasch, et al.
Melanoma Research|July 18, 2006
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genesSandra Bloethner, Kari Hemminki, Ranjit K Thirumaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy responseSelma Ugurel, Roland Houben, David Schrama, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Pageof 27